TY  - JOUR
A1  - Hartl, Maximilian J.
A1  - Bodem, Jochen
A1  - Jochheim, Fabian
A1  - Rethwilm, Axel
A1  - Rösch, Paul
A1  - Wöhrl, Birgitta M.
T1  - Regulation of foamy virus protease activity by viral RNA
JF  - Retrovirology
N2  - No abstract available.
KW  - Virologie
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-142248
VL  - 8
IS  - Suppl. 1
ER  - 
TY  - JOUR
A1  - Hess, Michael
A1  - Stritzker, Jochen
A1  - Härtl, Barbara
A1  - Sturm, Julia
A1  - Gentschev, Ivaylo
A1  - Szalay, Aladar
T1  - Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapies
N2  - Background: Oncolytic viral tumor therapy is an emerging field in the fight against cancer with rising numbers of clinical trials and the first clinically approved product (Adenovirus for the treatment of Head and Neck Cancer in China) in this field. Yet, until recently no general (bio)marker or reporter gene was described that could be used to evaluate successful tumor colonization and/or transgene expression in other biological therapies. Methods: Here, a bacterial glucuronidase (GusA) encoded by biological therapeutics (e.g. oncolytic viruses) was used as reporter system. Results: Using fluorogenic probes that were specifically activated by glucuronidase we could show 1) preferential activation in tumors, 2) rena l excretion of the activated fluorescent compounds and 3) reproducible detection of GusA in the serum of oncolytic vaccinia virus treated, tumor bearing mice in several tumor models. Time course studies revealed that reliable differentiation between tumor bearing and healthy mice can be done as early as 9 days post injection of the virus. Regarding the sensitivity of the newly developed assay system, we could show that a single infected tumor cell could be reliably detected in this assay. Conclusion: GusA therefore has the potential to be used as a general marker in the preclinical and clinical evaluation of (novel) biological therapies as well as being useful for the detection of rare cells such as circulating tumor cells
KW  - Virologie
KW  - beta-glucuronidase
KW  - oncolytic virus
KW  - cancer
KW  - reporter
KW  - fluorescent probe
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-69163
ER  - 
TY  - JOUR
A1  - Avota, Elita
A1  - Gassert, Evelyn
A1  - Schneider-Schaulies, Sibylle
T1  - Cytoskeletal Dynamics: Concepts in Measles Virus Replication and Immunomodulation
N2  - In common with most viruses, measles virus (MV) relies on the integrity of the cytoskeleton of its host cells both with regard to efficient replication in these cells, but also retention of their motility which favors viral dissemination. It is, however, the surface interaction of the viral glycoprotein (gp) complex with receptors present on lymphocytes and dendritic cells (DCs), that signals effective initiation of host cell cytoskeletal dynamics. For DCs, these may act to regulate processes as diverse as viral uptake and sorting, but also the ability of these cells to successfully establish and maintain functional immune synapses (IS) with T cells. In T cells, MV signaling causes actin cytoskeletal paralysis associated with a loss of polarization, adhesion and motility, which has been linked to activation of sphingomyelinases and subsequent accumulation of membrane ceramides. MV modulation of both DC and T cell cytoskeletal dynamics may be important for the understanding of MV immunosuppression at the cellular level.
KW  - Virologie
KW  - measles virus
KW  - cytoskeleton
KW  - sphingomyelinase
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-69092
ER  -